Implementation of CDK4/6 inhibitors (CDK4/6i) into clinical routine has revolutionized the treatment of patients with hormone receptor positive, HER2 negative advanced breast cancer (HR+/HER2− ABC). This evidence concerns the gene ERBB2 and breast cancer.